BR112017018872A2 - combinação de um antagonista pd-1 e eribulina para tratamento de câncer - Google Patents

combinação de um antagonista pd-1 e eribulina para tratamento de câncer

Info

Publication number
BR112017018872A2
BR112017018872A2 BR112017018872A BR112017018872A BR112017018872A2 BR 112017018872 A2 BR112017018872 A2 BR 112017018872A2 BR 112017018872 A BR112017018872 A BR 112017018872A BR 112017018872 A BR112017018872 A BR 112017018872A BR 112017018872 A2 BR112017018872 A2 BR 112017018872A2
Authority
BR
Brazil
Prior art keywords
eribulin
antagonist
combination
cancer treatment
combination therapies
Prior art date
Application number
BR112017018872A
Other languages
English (en)
Portuguese (pt)
Inventor
Berrak Erhan
Aktan Gursel
Matsui Junji
Yuan Ruirong
Karantza Vassiliki
Funahashi Yasuhiro
Original Assignee
Eisai R&D Man Co Ltd
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55586425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017018872(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd, Merck Sharp & Dohme filed Critical Eisai R&D Man Co Ltd
Publication of BR112017018872A2 publication Critical patent/BR112017018872A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112017018872A 2015-03-04 2016-03-03 combinação de um antagonista pd-1 e eribulina para tratamento de câncer BR112017018872A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128373P 2015-03-04 2015-03-04
US201562264068P 2015-12-07 2015-12-07
PCT/US2016/020734 WO2016141209A1 (en) 2015-03-04 2016-03-03 Combination of a pd-1 antagonist and eribulin for treating cancer

Publications (1)

Publication Number Publication Date
BR112017018872A2 true BR112017018872A2 (pt) 2018-05-29

Family

ID=55586425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018872A BR112017018872A2 (pt) 2015-03-04 2016-03-03 combinação de um antagonista pd-1 e eribulina para tratamento de câncer

Country Status (13)

Country Link
US (1) US10945990B2 (enExample)
EP (1) EP3265122B1 (enExample)
JP (1) JP6951248B2 (enExample)
KR (1) KR20170122810A (enExample)
CN (1) CN107810013B (enExample)
AU (1) AU2016226157B2 (enExample)
BR (1) BR112017018872A2 (enExample)
CA (1) CA2978311A1 (enExample)
IL (1) IL254133B (enExample)
MX (1) MX386547B (enExample)
RU (1) RU2737216C2 (enExample)
SG (1) SG11201706872SA (enExample)
WO (1) WO2016141209A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982060B2 (en) 2004-06-03 2011-07-19 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
MY160203A (en) 2009-03-30 2017-02-28 Eisai R&D Man Co Ltd Liposome composition
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3265122B1 (en) 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2988604C (en) * 2015-06-11 2023-05-09 Gabriel Kremmidiotis Pharmaceutical combination and uses thereof
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
KR20190082782A (ko) * 2016-10-14 2019-07-10 머크 샤프 앤드 돔 코포레이션 요로상피암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
US20190270802A1 (en) * 2016-10-21 2019-09-05 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist
WO2019017497A1 (en) * 2017-07-21 2019-01-24 Eisai R&D Management Co., Ltd. USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019240872A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
AU2019285640A1 (en) * 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
US11083705B2 (en) * 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
EP4051260A4 (en) * 2019-10-28 2023-12-06 Enzychem Lifesciences Corporation Methods and compositions for treatment of cancer
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK1087960T3 (da) 1998-06-17 2011-06-14 Eisai R&D Man Co Ltd Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
US7982060B2 (en) 2004-06-03 2011-07-19 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009046308A1 (en) 2007-10-03 2009-04-09 Eisai R & D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2528914B1 (en) 2010-01-26 2014-06-11 Eisai R&D Management Co., Ltd. Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs
WO2012119077A1 (en) 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
SG193489A1 (en) * 2011-03-18 2013-10-30 Eisai R&D Man Co Ltd Methods and compositions for predicting response to eribulin
RU2563346C2 (ru) 2011-03-31 2015-09-20 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
EP2928464A1 (en) * 2012-12-04 2015-10-14 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
LT2970473T (lt) * 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
BR112015030664A2 (pt) 2013-06-11 2017-07-25 Novartis Ag combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos
KR102265952B1 (ko) 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20160119867A (ko) * 2014-03-05 2016-10-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
SG11201609777SA (en) 2014-05-28 2016-12-29 Eisai R&D Man Co Ltd Use of eribulin in the treatment of cancer
EP3265122B1 (en) 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer

Also Published As

Publication number Publication date
RU2737216C2 (ru) 2020-11-26
CA2978311A1 (en) 2016-09-09
US10945990B2 (en) 2021-03-16
IL254133B (en) 2021-09-30
RU2017132877A3 (enExample) 2019-08-29
IL254133A0 (en) 2017-10-31
KR20170122810A (ko) 2017-11-06
JP6951248B2 (ja) 2021-10-20
WO2016141209A1 (en) 2016-09-09
US20180071247A1 (en) 2018-03-15
EP3265122A1 (en) 2018-01-10
SG11201706872SA (en) 2017-09-28
AU2016226157B2 (en) 2022-01-27
EP3265122B1 (en) 2022-05-04
JP2018508516A (ja) 2018-03-29
MX386547B (es) 2025-03-19
MX2017011206A (es) 2018-05-17
CN107810013B (zh) 2021-04-02
AU2016226157A1 (en) 2017-09-14
RU2017132877A (ru) 2019-04-05
CN107810013A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
MX390878B (es) Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112017004141A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112019007145A2 (pt) combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
BR112017025562A2 (pt) métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
MX2017013801A (es) Métodos para tratar el cáncer.
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017004140A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017006002A2 (pt) compostos de imidazopiridazina e seu uso
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BR112018001907A2 (pt) uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2764 DE 26-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.